ReviewGastroenterology report2019
Challenges and solutions in patient treatment strategies for stage II colon cancer.
Review in Gastroenterology report, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Integrated meta-analysis of colorectal cancer public proteomic datasets for biomarker discovery and validation.PLoS computational biology · 2024Pooled it
- Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma-a systematic review and meta-analysis.International journal of colorectal disease · 2023Pooled it
- Pooled it
- Genome-Scale Metabolic Modeling Identifies Synergistic Metabolites that Enhance 5-Fluorouracil Efficacy in Colon Cancer.Iranian biomedical journal · 2025Article
- Nucleotide metabolism-associated drug resistance gene NDUFA4L2 promotes colon cancer progression and 5-FU resistance.Scientific reports · 2025Article
- Anticancer Properties of Saccharomyces boulardii Metabolite Against Colon Cancer Cells.Probiotics and antimicrobial proteins · 2024Article
- Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer.Cancer research communications · 2023Article
- Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.Journal of managed care & specialty pharmacy · 2023Article
- DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer.Journal of the National Cancer Institute · 2023Article
- Article
- Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity.BMC chemistry · 2022Article
- The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.Annals of translational medicine · 2022Article
- InoperableMolecular and clinical oncology · 2022Article
- Morindone from Morinda citrifolia as a potential antiproliferative agent against colorectal cancer cell lines.PloS one · 2022Article
- Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.Translational cancer research · 2022Article
- A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.Frontiers in immunology · 2022Article
- Clinical characteristics and survival analysis of colorectal cancer in China: a retrospective cohort study with 13,328 patients from southern China.Gastroenterology report · 2021Article
- A new practical classification of desmoplastic reaction in endoscopic forceps biopsy of colorectal cancer.Histology and histopathology · 2021Article
- Automated Detection and Classification of Desmoplastic Reaction at the Colorectal Tumour Front Using Deep Learning.Cancers · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains one of the most common cancers worldwide and, despite improvements in treatment options for late-stage metastatic cancer, there are still questions surrounding how best to treat early-stage disease patients. Some recent advances have been made in the staging of cancer and improving the risk assessment of strategies for patient treatment. A number of high-risk features have been proposed that may help to stratify stage II cancer patients into groups that will truly benefit from adjuvant chemotherapy. Diagnostic tests are becoming available to measure these biomarkers, utilizing both currently available and novel technologies. This review will describe the challenges in treatment decisions for early-stage colon cancer and how personalized medicine can assist clinicians in making the best treatment choices for patients with stage II colon cancer in particular.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.